Weekly Recap: PALI-2108 clearances and $125M cash, no long-term debt

Palisade Bio, Inc. (NASDAQ:PALI) won FDA and Health Canada clearances to begin ASCENTRA-UC and ASCENTRA-CD Phase II trials with readouts due 2027—2028, backed by about $125M cash and no long-term debt, while HC Wainwright reiterates a Buy with a $7 target.Previous Week RecapThis is an AI-generated…